The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
November 22nd 2024
Children with obesity, asthma, and gastrointestinal disease had longer durations of stays compared with children without comorbidities.
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More
Rebyota Found Safe, Effective in Preventing Recurring Clostridioides Difficile Infection
October 16th 2023Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.
Read More
AI Is Revolutionizing Oncology With a Quantum Leap in Cancer Treatment
AI systems can detect minute anomalies often missed by the human eye, reducing false negatives.
Read More
Take a Moment to Reflect On How Far the Industry Has Come During American Pharmacists Month
October 16th 2023Margaret Ryman, BS, PharmD, BCPS, vice president of Health Systems at McKesson, discussed how she has seen the pharmacy field change and how she is celebrating this American Pharmacists Month.
Watch
Follow-Up Survey Indicates Cancer Centers Continue to Experience Chemotherapy Shortages
October 12th 2023Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.
Read More
Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer Disease
October 11th 2023Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Read More